Evidence map›Paper›PMID 38315083›Full record

ArticleChemistryOpen2024

Synthesis of compounds based on the active domain of cabotegravir and their application in inhibiting tumor cells activity.

Ruyue Yang, Wenhui Yue, Dong Hu, Guidan Wang, Longfei Mao, Jiahe Huang, Huili Wang, Gaofeng Liang

Abstract read
In one paragraph

Article in ChemistryOpen, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ruyue YangSchool of Basic Medicine and Forensic Medicine, Henan University of Science & Technology, Luoyang, 471023, China.ORCID 0009-0006-7394-0329
Wenhui YueSchool of Basic Medicine and Forensic Medicine, Henan University of Science & Technology, Luoyang, 471023, China.
Dong HuSchool of Basic Medicine and Forensic Medicine, Henan University of Science & Technology, Luoyang, 471023, China.
Guidan WangSchool of Medical Technology and Engineering, Henan University of Science & Technology, Luoyang, 471023, China.
Longfei MaoSchool of Basic Medicine and Forensic Medicine, Henan University of Science & Technology, Luoyang, 471023, China.
Jiahe HuangSchool of Basic Medicine and Forensic Medicine, Henan University of Science & Technology, Luoyang, 471023, China.
Huili WangUniversity of North Carolina Hospitals, 101 Manning Dr, Chapel Hill, Orange County, NC 27599, USA.
Gaofeng LiangSchool of Basic Medicine and Forensic Medicine, Henan University of Science & Technology, Luoyang, 471023, China.ORCID 0000-0003-0097-0296

Funding

the Key R&D project of Henan Province 221111310600the Special Foundation for Basic Research Program of Higher Education Institutions of Henan Province 22ZX005
6 · The paper itself

Abstract

Structural modification based on existing drugs, which ensures the safety of marketed drugs, is an essential approach in developing new drugs. In this study, we modified the structure of cabotegravir by introducing the front alkyne on the core structure through chemical reaction, resulting in the synthesis of 9 compounds resembling 1,2,3-triazoles. The potential of these new cabotegravir derivatives as tumor suppressors in gastrointestinal tumors was investigated. Based on the MTT experiment, most compounds showed a reduction in the viability of KYSE30 and HCT116 cells. Notably, derivatives 5b and 5h exhibited the most significant inhibitory effects. To further explore the effects of derivatives 5b and 5h on gastrointestinal tumors, KYSE30 cells were chosen as a representative cell line. Both derivatives can effectively curtail the migration and invasion capabilities of KYSE30 cells and induce apoptosis in a dose-dependent manner. We further demonstrated these derivatives induce cell apoptosis in KYSE30 cells by inhibiting the expression of Stat3 protein and Smad2/3 protein. Based on the above results, we suggest they show promise in developing drugs for esophageal squamous cell carcinoma.

Indexed as

Antineoplastic AgentsApoptosisCell MovementCatalytic DomainCell Line, TumorCell ProliferationCell SurvivalDiketopiperazinesDrug Screening Assays, AntitumorHCT116 CellsHumansPyridinesPyridonesSmad2 ProteinSmad3 ProteinSTAT3 Transcription FactorAntineoplastic AgentscabotegravirDiketopiperazinesPyridinesPyridonesSmad2 ProteinSMAD2 protein, humanSmad3 ProteinSMAD3 protein, humanSTAT3 protein, humanSTAT3 Transcription FactorapoptosisCabotegravirderivativesESCCKYSE30

Identifiers

PMID38315083
PMCPMC11230920

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.